<![CDATA[Fluoguide - precli data on FG001 effect in treatment cancer]]>Copenhagen, Denmark, 23 August 2021. FluoGuide A/S ("FluoGuide" or the "Company") is pleased to announce the first publication of preclinical data where the Company's compound FG001 is used as a photothermal therapy agent for treatment of cancer. The new feature of FG001 complements the surgical targeting and opens new opportunities for the realization of clinical and commercial potential of the Company's uPAR-targeting technology platform.

Link/Full details:
https://news.cision.com/fluoguide/r/publication-of-promising-preclinical-data-on-fg001s-effect-in-treatment-of-cancer,c3401276

Publication:
https://www.oncotarget.com/article/28013/pdf/

]]>https://dev.proinvestor.com/forum/topic/442984/fluoguide-precli-data-on-fg001-effect-in-treatment-cancerRSS for NodeSat, 04 Jul 2026 21:09:08 GMTMon, 23 Aug 2021 10:50:24 GMT60<![CDATA[Reply to Fluoguide - precli data on FG001 effect in treatment cancer on Wed, 25 Aug 2021 13:57:20 GMT]]>(PDF) Q2 2021 Regnskab og highlights for Fluoguide:
https://fluoguide.com/wp-content/uploads/FluoGuide-Q2-2021-report-Final.pdf

]]>https://dev.proinvestor.com/forum/post/9469634https://dev.proinvestor.com/forum/post/9469634Wed, 25 Aug 2021 13:57:20 GMT<![CDATA[Reply to Fluoguide - precli data on FG001 effect in treatment cancer on Wed, 25 Aug 2021 13:55:47 GMT]]>Q2 2021 - Regnskab - præsentation - YouTube

]]>https://dev.proinvestor.com/forum/post/9469633https://dev.proinvestor.com/forum/post/9469633Wed, 25 Aug 2021 13:55:47 GMT